A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms, animal toxicity, and expert literature with no new human data
PubMed 33054628 · doi:10.1080/1028415X.2020.1831262
What was done
This is a narrative review synthesizing published literature on the role of dietary fatty acids in neurodegeneration, with a specific focus on the pharmacological, therapeutic, and toxicological actions of erucic acid.
What was found
The abstract reports no numerical metrics or statistical effect sizes. It notes that while erucic acid causes myocardial lipidosis, heart lesions, and hepatic steatosis in animal studies—prompting regulatory intake limits—it is clinically used in combination with oleic acid for adrenoleukodystrophy without cardiotoxicity. Literature also indicates erucic acid modulates peroxisome proliferator-activated receptors (PPARs), inhibits elastase and thrombin, and may enhance cognitive function.
Why it matters
The review summarizes the dual nature of erucic acid, balancing its documented toxicological risks against potential neuroprotective and metabolic actions in neurodegenerative diseases.
Limits
As a narrative review, it lacks formal systematic screening criteria, quantitative meta-analysis, and reported study numbers. Much of the discussed pharmacology derives from animal or in vitro models rather than clinical trials.
Cited by
- supports Erucic acid has been associated with cardiac toxicities in animal studies.